For the year ending 2024-12-31.
| Income Statement | 2024-12-31 | |||
|---|---|---|---|---|
| Research and development | 13,006 | |||
| Impairment of long-lived assets | 2,705 | |||
| General and administrative | 15,460 | |||
| Total operating expenses | 31,171 | |||
| Loss from operations | -31,171 | |||
| Other expense, net | -265 | |||
| Interest income | 1,733 | |||
| Gain on warrant liability | 3,713 | |||
| Net loss | -25,990 | |||
| Unrealized gain (loss) on marketable debt securities | 39 | |||
| Comprehensive loss | -25,951 | |||
| Basic EPS | -1.54 | |||
| Diluted EPS | -1.54 | |||
| Basic Average Shares | 16,827,038 | |||
| Diluted Average Shares | 16,827,038 | |||
Unity Biotechnology, Inc. (UBX)
Unity Biotechnology, Inc. (UBX)